LDDA - The Liberal Democrat Disability Association

Representing those with disabilities within and outside the Lib Dems

NHS to review arthritis drugs use

10.57.07am UTC (GMT +0000) Tue 12th Jun 2007

The NHS treatment watchdog has agreed to review its guidance on the use of three drugs for rheumatoid arthritis. The National Institute for Health and Clinical Excellence (NICE) will look again at Humira, Enbrel and Remicade. Last year it ruled if a patient did not respond to one of the drugs - from a class known as anti-TNF medicines - they should not get another. But various charities, manufacturers and the Royal College of Nursing (RCN) appealed against that decision. The drugs will now undergo a further review of their NHS use.

The charity Arthritis Care said the original decision had meant "pain, disability and poverty" for many sufferers. Neil Betteridge, the chief executive, said: "People eligible to receive anti-TNF treatment are, by definition, people with severe rheumatoid arthritis - a disease which, if left untreated, leads to serious disability, often at a young age. If not properly treated, those with the most severe form die on average within five years. It is fantastic that people may now get a second bite of the cherry. There are three drugs of this type, and obviously patients want to try the other two if the first does not work for them. The alternative is often a life on incapacity benefit, with no opportunity to live fully and productively."

Mr Betteridge said the three anti-TNF drugs had a different make-up, and each was administered in a different way. "We argued that there is enough evidence to show that people often benefit from one anti-TNF having failed on another - quite enough evidence to justify the expense of permitting sequential use."

Around 400,000 people in the UK have rheumatoid arthritis, of which about 4,000 have severe rheumatoid arthritis.

A spokeswoman for NICE said: "Whilst the individual appeals were dismissed, the appeal panel decided that the appraisal committee needed to take another look at the use of a second anti-TNF treatment where there had been no response to a first anti-TNF treatment."

Bookmark this story at: del.icio.usdel.icio.us DiggDigg FacebookFacebook LibDigLibDig redditreddit StumbleUponStumbleUpon
Print this news story.
Comment on this news story.
Previous news story: Call to boost disabled employment (Tue 12th Jun 2007).
Next news story: Stem cell first for Parkinson's (Tue 12th Jun 2007).

Related News Stories:

Tue 15th Apr 2008:

Tue 15th Jan 2008:

Tue 27th Mar 2007:

Fri 17th Nov 2006:

Printed and hosted by Prater Raines Ltd, 82b Sandgate High Street, Folkestone CT20 3BX.
Published and promoted by LDDA - The Liberal Democrat Disability Association, 4 Cowley Street, London SW1P 3NB.
The views expressed are those of the party, not of the service provider.